All In Biotech

Drug Trial Radar · NCT06921850

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

43

Actual

Start

Apr 7, 2025

Primary completion

Dec 21, 2026

Study completion Mar 6, 2029

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BimekizumabDrug

    Bimekizumab will be administered at pre-specified timepoints.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Plasma bimekizumab concentrations at Week 16Time frame: At Week 16

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Hs0006 50708

    Roseville, California

  • Hs0006 50684

    Sacramento, California

  • Hs0006 50707

    Washington D.C., District of Columbia

  • Hs0006 50199

    Miami, Florida

  • Hs0006 50712

    Bowling Green, Kentucky

  • Hs0006 50178

    Clarkston, Michigan

  • Hs0006 50710

    Fort Gratiot, Michigan

  • Hs0006 50711

    Troy, Michigan

  • Hs0006 50706

    Chapel Hill, North Carolina

  • Hs0006 50202

    Fairborn, Ohio

  • Hs0006 50201

    Arlington, Texas

  • Hs0006 40326

    Berlin, Germany

  • Hs0006 40625

    Lodz, Poland

  • Hs0006 40761

    Warsaw, Poland

  • Hs0006 40095

    Wroclaw, Poland

  • Hs0006 40845

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.